We are enclosing herewith the Press Release on receipt of regulatory approval and first commercial order from leading marketplace Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Veerhealth Care received mandatory regulatory approval from Gujarat's Food and Drug Authority to manufacture and supply personal care products for a leading Indian marketplace company. It also secured its first commercial trial order worth around ₹0.48 crores under a contract manufacturing agreement, covering skin care and face care products to be delivered in 30 days, with management expecting repeat orders. For FY 2025-26, the company guided for total revenues of ₹35-40 crores with a PAT margin of 10%, and a longer-term target of ₹100 crores in revenue over the next 24-36 months. The company is now operating at full capacity to meet rising domestic and export demand, and is expecting USFDA clearance for its medical devices category.
Mildly positive — the regulatory clearance unlocks a new contract manufacturing revenue stream with a major e-commerce client, and explicit FY26 revenue/PAT guidance provides earnings visibility. However, the initial order size (~₹0.48 cr) is small relative to the ₹35-40 cr revenue guidance (~1.4%), so the stock impact depends on whether repeat and larger orders materialize.